Clinical Trial Detail

NCT ID NCT02734290
Title Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Providence Health & Services
Indications

triple-receptor negative breast cancer

Therapies

Capecitabine + Pembrolizumab

Paclitaxel + Pembrolizumab

Age Groups: adult

No variant requirements are available.